sirolimus + ACE inhibitor + statin

This entry refers to a combination therapy involving sirolimus, an angiotensin-converting enzyme (ACE) inhibitor, and a statin. Sirolimus is an mTOR inhibitor immunosuppressant primarily used to prevent organ transplant rejection and treat certain rare diseases. ACE inhibitors are a class of drugs that inhibit the conversion of angiotensin I to angiotensin II, thereby lowering blood pressure and providing renal protection. Statins are HMG-CoA reductase inhibitors used to lower cholesterol levels and reduce cardiovascular risk. The combination has been studied in patients with poor prognosis IgA nephropathy, where low-dose sirolimus added to enalapril (an ACE inhibitor) and a statin was found to be safe, stabilize renal function, and reduce glomerular proliferative lesions[1][2][3]. However, this regimen carries potential risks for drug interactions: - Sirolimus combined with ACE inhibitors may increase the risk of angioedema[7]. - Sirolimus combined with statins can increase the risk of muscle damage due to elevated statin levels[7]. This combination is not marketed as a fixed-dose product but represents an off-label or investigational multi-drug regimen for specific clinical scenarios.